Lung Cancer Genomic Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Component (Products v/s Services), By Technology (Next Generation Sequencing, Polymerase Chain Reactions, Fluorescence In Situ Hybridization (FISH)/In Situ Hybridization (ISH), Others), By Panel Type (Single Panel v/s Multi-Gene Panel), By Sample Type (Tissue Biopsy v/s Liquid Biopsy), By End User (Academic & Research Institutions, Hospitals & Clinics, Diagnostic Laboratories, Others), By Region & Competition, 2021-2031F
The Global Lung Cancer Genomic Testing Market will grow from USD 2.17 Billion in 2025 to USD 3.76 Billion by 2031 at a 9.59% CAGR. Lung cancer genomic testing involves the molecular analysis of tumor tissue or liquid biopsies to identify specific genetic alterations such as EGFR mutations or ALK rearrangements that dictate the selection of targeted therapies. The market is primarily propelled by the clinical transition toward personalized medicine and the stringent regulatory requirement for companion diagnostics to authorize the use of novel oncology drugs.
Key Market Drivers
The Rising Global Incidence and Prevalence of Lung Cancer serves as the foundational catalyst for the genomic testing market, creating an expanding patient pool that necessitates precise molecular diagnosis. As the burden of lung malignancy remains high globally, healthcare systems are increasingly mandating comprehensive biomarker testing for all newly diagnosed patients to determine the most effective management strategies. This volume-driven demand is evidenced by the sheer scale of diagnoses in major markets.
Key Market Challenges
The inconsistent reimbursement landscape for next-generation sequencing constitutes a substantial barrier hampering the growth of the Global Lung Cancer Genomic Testing Market. While clinical guidelines increasingly recommend comprehensive profiling, the lack of uniform payer coverage creates severe economic friction that disconnects clinical availability from patient accessibility. Diagnostic developers face restricted revenue potential as healthcare providers often hesitate to order advanced genomic profiling due to uncertainty regarding payment authorization.
Key Market Trends
The transition from single-gene assays to comprehensive next-generation sequencing (NGS) panels is reshaping the diagnostic standard for lung malignancy, driven by the need to efficiently identify multiple actionable alterations from limited tissue samples. Clinicians are increasingly abandoning iterative single-biomarker testing, which risks tissue exhaustion, in favor of broad genomic profiling that captures co-occurring mutations and complex signatures like tumor mutational burden in a single workflow. This consolidation is critical for matching patients to the growing array of targeted therapies without the latency of sequential testing.
Key Market Players
In this report, the Global Lung Cancer Genomic Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Lung Cancer Genomic Testing Market.
Available Customizations:
Global Lung Cancer Genomic Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Key Market Drivers
The Rising Global Incidence and Prevalence of Lung Cancer serves as the foundational catalyst for the genomic testing market, creating an expanding patient pool that necessitates precise molecular diagnosis. As the burden of lung malignancy remains high globally, healthcare systems are increasingly mandating comprehensive biomarker testing for all newly diagnosed patients to determine the most effective management strategies. This volume-driven demand is evidenced by the sheer scale of diagnoses in major markets.
Key Market Challenges
The inconsistent reimbursement landscape for next-generation sequencing constitutes a substantial barrier hampering the growth of the Global Lung Cancer Genomic Testing Market. While clinical guidelines increasingly recommend comprehensive profiling, the lack of uniform payer coverage creates severe economic friction that disconnects clinical availability from patient accessibility. Diagnostic developers face restricted revenue potential as healthcare providers often hesitate to order advanced genomic profiling due to uncertainty regarding payment authorization.
Key Market Trends
The transition from single-gene assays to comprehensive next-generation sequencing (NGS) panels is reshaping the diagnostic standard for lung malignancy, driven by the need to efficiently identify multiple actionable alterations from limited tissue samples. Clinicians are increasingly abandoning iterative single-biomarker testing, which risks tissue exhaustion, in favor of broad genomic profiling that captures co-occurring mutations and complex signatures like tumor mutational burden in a single workflow. This consolidation is critical for matching patients to the growing array of targeted therapies without the latency of sequential testing.
Key Market Players
- QIAGEN NV
- Agilent Technologies Inc.
- Thermo Fisher Scientific Inc.
- Quest Diagnostics Incorporated
- Laboratory Corporation of America Holdings
- CENTOGENE N.V.
- BGI Genomics Co. Ltd.
- CeGaT GmbH
- Illumina Inc.
- F. Hoffmann-La Roche Ltd
In this report, the Global Lung Cancer Genomic Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Lung Cancer Genomic Testing Market, By Component:
- Products v/s Services
- Lung Cancer Genomic Testing Market, By Technology:
- Next Generation Sequencing
- Polymerase Chain Reactions
- Fluorescence In Situ Hybridization (FISH)/In Situ Hybridization (ISH)
- Others
- Lung Cancer Genomic Testing Market, By Panel Type:
- Single Panel v/s Multi-Gene Panel
- Lung Cancer Genomic Testing Market, By Sample Type:
- Tissue Biopsy v/s Liquid Biopsy
- Lung Cancer Genomic Testing Market, By End User:
- Academic & Research Institutions
- Hospitals & Clinics
- Diagnostic Laboratories
- Others
- Lung Cancer Genomic Testing Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Lung Cancer Genomic Testing Market.
Available Customizations:
Global Lung Cancer Genomic Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL LUNG CANCER GENOMIC TESTING MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Component (Products v/s Services)
5.2.2. By Technology (Next Generation Sequencing, Polymerase Chain Reactions, Fluorescence In Situ Hybridization (FISH)/In Situ Hybridization (ISH), Others)
5.2.3. By Panel Type (Single Panel v/s Multi-Gene Panel)
5.2.4. By Sample Type (Tissue Biopsy v/s Liquid Biopsy)
5.2.5. By End User (Academic & Research Institutions, Hospitals & Clinics, Diagnostic Laboratories, Others)
5.2.6. By Region
5.2.7. By Company (2025)
5.3. Market Map
6. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Component
6.2.2. By Technology
6.2.3. By Panel Type
6.2.4. By Sample Type
6.2.5. By End User
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Lung Cancer Genomic Testing Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Component
6.3.1.2.2. By Technology
6.3.1.2.3. By Panel Type
6.3.1.2.4. By Sample Type
6.3.1.2.5. By End User
6.3.2. Canada Lung Cancer Genomic Testing Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Component
6.3.2.2.2. By Technology
6.3.2.2.3. By Panel Type
6.3.2.2.4. By Sample Type
6.3.2.2.5. By End User
6.3.3. Mexico Lung Cancer Genomic Testing Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Component
6.3.3.2.2. By Technology
6.3.3.2.3. By Panel Type
6.3.3.2.4. By Sample Type
6.3.3.2.5. By End User
7. EUROPE LUNG CANCER GENOMIC TESTING MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Component
7.2.2. By Technology
7.2.3. By Panel Type
7.2.4. By Sample Type
7.2.5. By End User
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Lung Cancer Genomic Testing Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Component
7.3.1.2.2. By Technology
7.3.1.2.3. By Panel Type
7.3.1.2.4. By Sample Type
7.3.1.2.5. By End User
7.3.2. France Lung Cancer Genomic Testing Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Component
7.3.2.2.2. By Technology
7.3.2.2.3. By Panel Type
7.3.2.2.4. By Sample Type
7.3.2.2.5. By End User
7.3.3. United Kingdom Lung Cancer Genomic Testing Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Component
7.3.3.2.2. By Technology
7.3.3.2.3. By Panel Type
7.3.3.2.4. By Sample Type
7.3.3.2.5. By End User
7.3.4. Italy Lung Cancer Genomic Testing Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Component
7.3.4.2.2. By Technology
7.3.4.2.3. By Panel Type
7.3.4.2.4. By Sample Type
7.3.4.2.5. By End User
7.3.5. Spain Lung Cancer Genomic Testing Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Component
7.3.5.2.2. By Technology
7.3.5.2.3. By Panel Type
7.3.5.2.4. By Sample Type
7.3.5.2.5. By End User
8. ASIA PACIFIC LUNG CANCER GENOMIC TESTING MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Component
8.2.2. By Technology
8.2.3. By Panel Type
8.2.4. By Sample Type
8.2.5. By End User
8.2.6. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Lung Cancer Genomic Testing Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Component
8.3.1.2.2. By Technology
8.3.1.2.3. By Panel Type
8.3.1.2.4. By Sample Type
8.3.1.2.5. By End User
8.3.2. India Lung Cancer Genomic Testing Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Component
8.3.2.2.2. By Technology
8.3.2.2.3. By Panel Type
8.3.2.2.4. By Sample Type
8.3.2.2.5. By End User
8.3.3. Japan Lung Cancer Genomic Testing Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Component
8.3.3.2.2. By Technology
8.3.3.2.3. By Panel Type
8.3.3.2.4. By Sample Type
8.3.3.2.5. By End User
8.3.4. South Korea Lung Cancer Genomic Testing Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Component
8.3.4.2.2. By Technology
8.3.4.2.3. By Panel Type
8.3.4.2.4. By Sample Type
8.3.4.2.5. By End User
8.3.5. Australia Lung Cancer Genomic Testing Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Component
8.3.5.2.2. By Technology
8.3.5.2.3. By Panel Type
8.3.5.2.4. By Sample Type
8.3.5.2.5. By End User
9. MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Component
9.2.2. By Technology
9.2.3. By Panel Type
9.2.4. By Sample Type
9.2.5. By End User
9.2.6. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Lung Cancer Genomic Testing Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Component
9.3.1.2.2. By Technology
9.3.1.2.3. By Panel Type
9.3.1.2.4. By Sample Type
9.3.1.2.5. By End User
9.3.2. UAE Lung Cancer Genomic Testing Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Component
9.3.2.2.2. By Technology
9.3.2.2.3. By Panel Type
9.3.2.2.4. By Sample Type
9.3.2.2.5. By End User
9.3.3. South Africa Lung Cancer Genomic Testing Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Component
9.3.3.2.2. By Technology
9.3.3.2.3. By Panel Type
9.3.3.2.4. By Sample Type
9.3.3.2.5. By End User
10. SOUTH AMERICA LUNG CANCER GENOMIC TESTING MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Component
10.2.2. By Technology
10.2.3. By Panel Type
10.2.4. By Sample Type
10.2.5. By End User
10.2.6. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Lung Cancer Genomic Testing Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Component
10.3.1.2.2. By Technology
10.3.1.2.3. By Panel Type
10.3.1.2.4. By Sample Type
10.3.1.2.5. By End User
10.3.2. Colombia Lung Cancer Genomic Testing Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Component
10.3.2.2.2. By Technology
10.3.2.2.3. By Panel Type
10.3.2.2.4. By Sample Type
10.3.2.2.5. By End User
10.3.3. Argentina Lung Cancer Genomic Testing Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Component
10.3.3.2.2. By Technology
10.3.3.2.3. By Panel Type
10.3.3.2.4. By Sample Type
10.3.3.2.5. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL LUNG CANCER GENOMIC TESTING MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. QIAGEN NV
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Agilent Technologies Inc.
15.3. Thermo Fisher Scientific Inc.
15.4. Quest Diagnostics Incorporated
15.5. Laboratory Corporation of America Holdings
15.6. CENTOGENE N.V.
15.7. BGI Genomics Co. Ltd.
15.8. CeGaT GmbH
15.9. Illumina Inc.
15.10. F. Hoffmann-La Roche Ltd
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL LUNG CANCER GENOMIC TESTING MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Component (Products v/s Services)
5.2.2. By Technology (Next Generation Sequencing, Polymerase Chain Reactions, Fluorescence In Situ Hybridization (FISH)/In Situ Hybridization (ISH), Others)
5.2.3. By Panel Type (Single Panel v/s Multi-Gene Panel)
5.2.4. By Sample Type (Tissue Biopsy v/s Liquid Biopsy)
5.2.5. By End User (Academic & Research Institutions, Hospitals & Clinics, Diagnostic Laboratories, Others)
5.2.6. By Region
5.2.7. By Company (2025)
5.3. Market Map
6. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Component
6.2.2. By Technology
6.2.3. By Panel Type
6.2.4. By Sample Type
6.2.5. By End User
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Lung Cancer Genomic Testing Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Component
6.3.1.2.2. By Technology
6.3.1.2.3. By Panel Type
6.3.1.2.4. By Sample Type
6.3.1.2.5. By End User
6.3.2. Canada Lung Cancer Genomic Testing Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Component
6.3.2.2.2. By Technology
6.3.2.2.3. By Panel Type
6.3.2.2.4. By Sample Type
6.3.2.2.5. By End User
6.3.3. Mexico Lung Cancer Genomic Testing Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Component
6.3.3.2.2. By Technology
6.3.3.2.3. By Panel Type
6.3.3.2.4. By Sample Type
6.3.3.2.5. By End User
7. EUROPE LUNG CANCER GENOMIC TESTING MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Component
7.2.2. By Technology
7.2.3. By Panel Type
7.2.4. By Sample Type
7.2.5. By End User
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Lung Cancer Genomic Testing Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Component
7.3.1.2.2. By Technology
7.3.1.2.3. By Panel Type
7.3.1.2.4. By Sample Type
7.3.1.2.5. By End User
7.3.2. France Lung Cancer Genomic Testing Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Component
7.3.2.2.2. By Technology
7.3.2.2.3. By Panel Type
7.3.2.2.4. By Sample Type
7.3.2.2.5. By End User
7.3.3. United Kingdom Lung Cancer Genomic Testing Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Component
7.3.3.2.2. By Technology
7.3.3.2.3. By Panel Type
7.3.3.2.4. By Sample Type
7.3.3.2.5. By End User
7.3.4. Italy Lung Cancer Genomic Testing Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Component
7.3.4.2.2. By Technology
7.3.4.2.3. By Panel Type
7.3.4.2.4. By Sample Type
7.3.4.2.5. By End User
7.3.5. Spain Lung Cancer Genomic Testing Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Component
7.3.5.2.2. By Technology
7.3.5.2.3. By Panel Type
7.3.5.2.4. By Sample Type
7.3.5.2.5. By End User
8. ASIA PACIFIC LUNG CANCER GENOMIC TESTING MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Component
8.2.2. By Technology
8.2.3. By Panel Type
8.2.4. By Sample Type
8.2.5. By End User
8.2.6. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Lung Cancer Genomic Testing Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Component
8.3.1.2.2. By Technology
8.3.1.2.3. By Panel Type
8.3.1.2.4. By Sample Type
8.3.1.2.5. By End User
8.3.2. India Lung Cancer Genomic Testing Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Component
8.3.2.2.2. By Technology
8.3.2.2.3. By Panel Type
8.3.2.2.4. By Sample Type
8.3.2.2.5. By End User
8.3.3. Japan Lung Cancer Genomic Testing Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Component
8.3.3.2.2. By Technology
8.3.3.2.3. By Panel Type
8.3.3.2.4. By Sample Type
8.3.3.2.5. By End User
8.3.4. South Korea Lung Cancer Genomic Testing Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Component
8.3.4.2.2. By Technology
8.3.4.2.3. By Panel Type
8.3.4.2.4. By Sample Type
8.3.4.2.5. By End User
8.3.5. Australia Lung Cancer Genomic Testing Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Component
8.3.5.2.2. By Technology
8.3.5.2.3. By Panel Type
8.3.5.2.4. By Sample Type
8.3.5.2.5. By End User
9. MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Component
9.2.2. By Technology
9.2.3. By Panel Type
9.2.4. By Sample Type
9.2.5. By End User
9.2.6. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Lung Cancer Genomic Testing Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Component
9.3.1.2.2. By Technology
9.3.1.2.3. By Panel Type
9.3.1.2.4. By Sample Type
9.3.1.2.5. By End User
9.3.2. UAE Lung Cancer Genomic Testing Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Component
9.3.2.2.2. By Technology
9.3.2.2.3. By Panel Type
9.3.2.2.4. By Sample Type
9.3.2.2.5. By End User
9.3.3. South Africa Lung Cancer Genomic Testing Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Component
9.3.3.2.2. By Technology
9.3.3.2.3. By Panel Type
9.3.3.2.4. By Sample Type
9.3.3.2.5. By End User
10. SOUTH AMERICA LUNG CANCER GENOMIC TESTING MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Component
10.2.2. By Technology
10.2.3. By Panel Type
10.2.4. By Sample Type
10.2.5. By End User
10.2.6. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Lung Cancer Genomic Testing Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Component
10.3.1.2.2. By Technology
10.3.1.2.3. By Panel Type
10.3.1.2.4. By Sample Type
10.3.1.2.5. By End User
10.3.2. Colombia Lung Cancer Genomic Testing Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Component
10.3.2.2.2. By Technology
10.3.2.2.3. By Panel Type
10.3.2.2.4. By Sample Type
10.3.2.2.5. By End User
10.3.3. Argentina Lung Cancer Genomic Testing Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Component
10.3.3.2.2. By Technology
10.3.3.2.3. By Panel Type
10.3.3.2.4. By Sample Type
10.3.3.2.5. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL LUNG CANCER GENOMIC TESTING MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. QIAGEN NV
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Agilent Technologies Inc.
15.3. Thermo Fisher Scientific Inc.
15.4. Quest Diagnostics Incorporated
15.5. Laboratory Corporation of America Holdings
15.6. CENTOGENE N.V.
15.7. BGI Genomics Co. Ltd.
15.8. CeGaT GmbH
15.9. Illumina Inc.
15.10. F. Hoffmann-La Roche Ltd
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
